IBB
$207.96+1.30%
as of close, Oct 5, 2026
☾ AH $207.96 +1.30%
iShares Biotechnology ETFETF · Themes
IBB holdings (2026)
All 247 positions in iShares Biotechnology ETF, ranked by portfolio weight — led by AMGN at 8.0%. Weights come from the fund's own SEC N-PORT filing and update daily with prices; positions in stocks ChartRow doesn't track still appear, ranked by weight, without returns. Not investment advice.
Weights are the Jun 30, 2026 SEC filing rolled forward on each holding’s price move (as of market close, Oct 5, 2026) — an estimate of today, not the filed figure. Switch the table below to see them exactly as filed.
Holdings
247
positions in the latest filing
Largest holding
8.0%
AMGN · estimated today
Top 10 weight
49%
concentration · estimated today
On ChartRow
67.9%
fund weight in tickers ChartRow tracks
Filed
Jun 30, 2026
SEC N-PORT report date
Top 10 holdings#
CompanyWeight1D
7Argenx SE
3.4%—
Sector weights#
SectorWeight
Healthcare
66.5%
Not on ChartRow
32.1%
Industrials
0.8%
Technology
0.6%
Estimated portfolio characteristics#
Median P/E
29.7
per member, trailing
P/B
7.0
weighted
Dividend yield
0.58%
weighted
Earnings growth
-38.7%
aggregate TTM, YoY
Avg market cap
$85B
weighted
Estimated by our own bottom-up analysis of the fund’s SEC-filed holdings, covering 68% of portfolio weight (55% carries a valid trailing P/E). Funds publish similar figures on their own sites; ours are recomputed daily from public data.
IBB holdings by weight
1–100 of 247Weightsthe Jun 30, 2026 filing rolled forward on price — an estimate (as of market close, Oct 5, 2026)
| # | Company | Weight | Price | 1D | YTD | 1Y | Mkt cap |
|---|---|---|---|---|---|---|---|
| 1 | AMGNAmgen Inc. | 7.96% | $403.09 | +0.01% | +23.12% | +35.28% | $218B |
| 2 | VRTXVertex Pharmaceuticals Incorporated | 7.44% | $503.70 | -0.20% | +11.06% | +24.85% | $128B |
| 3 | GILDGilead Sciences Inc. | 7.15% | $144.66 | -0.06% | +17.83% | +28.34% | $179B |
| 4 | MRNAModerna Inc. | 5.18% | $203.21 | +6.95% | +589.08% | +613.27% | $81B |
| 5 | REGNRegeneron Pharmaceuticals Inc. | 5.18% | $726.84 | -1.14% | -5.88% | +21.08% | $75B |
| 6 | NTRANatera Inc. | 4.14% | $425.65 | +3.73% | +85.80% | +154.34% | $61B |
| 7 | Argenx SE | 3.43% | — | — | — | — | — |
| 8 | ILMNIllumina Inc. | 3.16% | $293.94 | +7.65% | +123.92% | +187.59% | $44B |
| 9 | RVMDRevolution Medicines Inc. | 2.81% | $207.88 | +0.60% | +160.74% | +344.62% | $45B |
| 10 | BIIBBiogen Inc. | 2.32% | $223.38 | +1.59% | +27.05% | +39.85% | $33B |
| 11 | ALNYAlnylam Pharmaceuticals Inc. | 2.08% | $220.02 | +0.14% | -44.70% | -51.82% | $29B |
| 12 | BeOne Medicines Ltd. | 1.62% | — | — | — | — | — |
| 13 | INCYIncyte Corp. | 1.60% | $114.14 | -1.01% | +15.55% | +31.41% | $23B |
| 14 | INSMInsmed Incorporated | 1.59% | $103.88 | -6.52% | -40.34% | -33.93% | $23B |
| 15 | UTHRUnited Therapeutics Corporation | 1.57% | $536.66 | -0.93% | +10.09% | +18.39% | $23B |
| 16 | ROIVRoivant Sciences Ltd. | 1.32% | $35.81 | +0.25% | +64.88% | +121.27% | $26B |
| 17 | CRLCharles River Laboratories | 1.07% | $310.95 | +7.15% | +55.79% | +75.25% | $15B |
| 18 | Genmab A/S | 1.02% | — | — | — | — | — |
| 19 | EXELExelixis Inc. | 1.02% | $58.86 | +0.80% | +34.27% | +46.79% | $15B |
| 20 | MEDPMedpace Holdings Inc. | 1.02% | $620.64 | +3.53% | +10.48% | +16.53% | $17B |
| 21 | NBIXNeurocrine Biosciences Inc. | 1.01% | $144.32 | +0.80% | +1.68% | +5.24% | $15B |
| 22 | ASNDAscendis Pharma A/S Ordinary Share | 1.00% | $228.20 | +0.14% | +6.94% | +11.75% | $14B |
| 23 | Ionis Pharmaceuticals, Inc. | 0.91% | — | — | — | — | — |
| 24 | HALOHalozyme Therapeutics Inc. | 0.91% | $108.32 | -1.40% | +60.94% | +57.02% | $12B |
| 25 | TWSTTwist Bioscience Corporation | 0.87% | $204.98 | +8.64% | +546.28% | +559.80% | $13B |
| 26 | TECHBio-Techne | 0.81% | $72.60 | +0.27% | +23.41% | +15.30% | $11B |
| 27 | BBIOBridgeBio Pharma Inc. | 0.80% | $66.17 | -1.61% | -13.53% | +25.12% | $13B |
| 28 | TXG10x Genomics Inc. | 0.78% | $97.93 | +4.74% | +499.26% | +666.59% | $13B |
| 29 | BMRNBioMarin Pharmaceutical Inc. | 0.78% | $57.56 | +0.66% | -3.18% | +3.81% | $11B |
| 30 | MDGLMadrigal Pharmaceuticals Inc. | 0.76% | $493.60 | -1.16% | -15.24% | +11.42% | $11B |
| 31 | TEMTempus AI Inc. | 0.63% | $83.54 | +9.02% | +41.49% | -8.85% | $15B |
| 32 | Abivax SA | 0.61% | — | — | — | — | — |
| 33 | KRYSKrystal Biotech Inc. | 0.61% | $335.08 | +3.97% | +35.82% | +82.62% | $10B |
| 34 | Alkermes plc | 0.61% | — | — | — | — | — |
| 35 | BioNTech SE | 0.60% | — | — | — | — | — |
| 36 | ARWRArrowhead Pharmaceuticals Inc. | 0.59% | $62.37 | -2.84% | -6.09% | +72.62% | $9B |
| 37 | Vaxcyte, Inc. | 0.58% | — | — | — | — | — |
| 38 | Kymera Therapeutics, Inc. | 0.58% | — | — | — | — | — |
| 39 | AXSMAxsome Therapeutics Inc. | 0.54% | $177.11 | -1.19% | -3.04% | +47.20% | $9B |
| 40 | Apogee Therapeutics, Inc. | 0.54% | — | — | — | — | — |
| 41 | Protagonist Therapeutics, Inc. | 0.53% | — | — | — | — | — |
| 42 | CYTKCytokinetics Incorporated | 0.53% | $62.75 | -4.34% | -1.32% | +10.06% | $8B |
| 43 | PRAXPraxis Precision Medicines Inc. | 0.53% | $284.00 | -3.90% | -3.79% | +421.44% | $8B |
| 44 | Rhythm Pharmaceuticals, Inc. | 0.52% | — | — | — | — | — |
| 45 | Repligen Corp. | 0.52% | — | — | — | — | — |
| 46 | Spyre Therapeutics, Inc. | 0.49% | — | — | — | — | — |
| 47 | Bruker Corp. | 0.48% | — | — | — | — | — |
| 48 | PTC Therapeutics, Inc. | 0.47% | — | — | — | — | — |
| 49 | Nuvalent, Inc. | 0.46% | — | — | — | — | — |
| 50 | Mirum Pharmaceuticals, Inc. | 0.41% | — | — | — | — | — |
| 51 | Cogent Biosciences, Inc. | 0.41% | — | — | — | — | — |
| 52 | Xenon Pharmaceuticals, Inc. | 0.39% | — | — | — | — | — |
| 53 | Scholar Rock Holding Corp. | 0.38% | — | — | — | — | — |
| 54 | Travere Therapeutics, Inc. | 0.37% | — | — | — | — | — |
| 55 | Definium Therapeutics, Inc. | 0.35% | — | — | — | — | — |
| 56 | CRISPR Therapeutics AG | 0.35% | — | — | — | — | — |
| 57 | Oruka Therapeutics, Inc. | 0.34% | — | — | — | — | — |
| 58 | Veracyte, Inc. | 0.33% | — | — | — | — | — |
| 59 | Legend Biotech Corp. | 0.31% | — | — | — | — | — |
| 60 | ACADIA Pharmaceuticals, Inc. | 0.30% | — | — | — | — | — |
| 61 | CG oncology, Inc. | 0.29% | — | — | — | — | — |
| 62 | Denali Therapeutics, Inc. | 0.27% | — | — | — | — | — |
| 63 | Crinetics Pharmaceuticals, Inc. | 0.26% | — | — | — | — | — |
| 64 | Erasca, Inc. | 0.24% | — | — | — | — | — |
| 65 | Tango Therapeutics, Inc. | 0.24% | — | — | — | — | — |
| 66 | Adaptive Biotechnologies Corp. | 0.24% | — | — | — | — | — |
| 67 | ImmunityBio, Inc. | 0.23% | — | — | — | — | — |
| 68 | Beam Therapeutics, Inc. | 0.23% | — | — | — | — | — |
| 69 | Edgewise Therapeutics, Inc. | 0.23% | — | — | — | — | — |
| 70 | Structure Therapeutics, Inc. | 0.22% | — | — | — | — | — |
| 71 | Immunovant, Inc. | 0.22% | — | — | — | — | — |
| 72 | Ideaya Biosciences, Inc. | 0.22% | — | — | — | — | — |
| 73 | Ultragenyx Pharmaceutical, Inc. | 0.21% | — | — | — | — | — |
| 74 | Dyne Therapeutics, Inc. | 0.21% | — | — | — | — | — |
| 75 | Arcutis Biotherapeutics, Inc. | 0.21% | — | — | — | — | — |
| 76 | Newamsterdam Pharma Co. NV | 0.19% | — | — | — | — | — |
| 77 | GRAIL, Inc. | 0.19% | — | — | — | — | — |
| 78 | Relay Therapeutics, Inc. | 0.19% | — | — | — | — | — |
| 79 | uniQure NV | 0.18% | — | — | — | — | — |
| 80 | Arcus Biosciences, Inc. | 0.18% | — | — | — | — | — |
| 81 | Tarsus Pharmaceuticals, Inc. | 0.18% | — | — | — | — | — |
| 82 | Vera Therapeutics, Inc. | 0.18% | — | — | — | — | — |
| 83 | Enliven Therapeutics, Inc. | 0.17% | — | — | — | — | — |
| 84 | Nurix Therapeutics, Inc. | 0.17% | — | — | — | — | — |
| 85 | Alumis, Inc. | 0.17% | — | — | — | — | — |
| 86 | SMMTSummit Therapeutics Inc. Common Stock | 0.17% | $17.29 | +3.16% | -1.26% | -19.41% | $14B |
| 87 | Kodiak Sciences, Inc. | 0.16% | — | — | — | — | — |
| 88 | Vericel Corp. | 0.16% | — | — | — | — | — |
| 89 | Intellia Therapeutics, Inc. | 0.16% | — | — | — | — | — |
| 90 | Caris Life Sciences, Inc. | 0.16% | — | — | — | — | — |
| 91 | BioCryst Pharmaceuticals, Inc. | 0.15% | — | — | — | — | — |
| 92 | Agios Pharmaceuticals, Inc. | 0.15% | — | — | — | — | — |
| 93 | Disc Medicine, Inc. | 0.14% | — | — | — | — | — |
| 94 | Aurinia Pharmaceuticals, Inc. | 0.14% | — | — | — | — | — |
| 95 | ADMA Biologics, Inc. | 0.13% | — | — | — | — | — |
| 96 | Biohaven Ltd. | 0.13% | — | — | — | — | — |
| 97 | Zymeworks, Inc. | 0.13% | — | — | — | — | — |
| 98 | AnaptysBio, Inc. | 0.13% | — | — | — | — | — |
| 99 | AbCellera Biologics, Inc. | 0.13% | — | — | — | — | — |
| 100 | Sarepta Therapeutics, Inc. | 0.13% | — | — | — | — | — |
Methodology#
Holdings and weights are sourced from the fund’s portfolio as disclosed to the SEC on Form N-PORT — a public filing. Portfolio filings are quarterly (public ~60 days after quarter end), so we anchor on the latest one and roll each weight forward daily by that holding’s price move, keeping the numbers current between filings; positions in stocks ChartRow doesn’t track carry their filed weight unchanged and show “—” where we have no data. Returns are total returns (dividends reinvested). One row per company, not per ticker: when a fund holds more than one share class of the same company (Alphabet’s GOOGL and GOOG, for example), we combine them into a single row whose weight is the sum of its classes. Past performance does not predict future returns; not investment advice.
FAQ#
- What are the top 10 holdings of IBB?
- IBB's top 10 holdings are Amgen Inc. (AMGN), 8.0%; Vertex Pharmaceuticals Incorporated (VRTX), 7.4%; Gilead Sciences Inc. (GILD), 7.1%; Moderna Inc. (MRNA), 5.2%; Regeneron Pharmaceuticals Inc. (REGN), 5.2%; Natera Inc. (NTRA), 4.1%; Argenx SE, 3.4%; Illumina Inc. (ILMN), 3.2%; Revolution Medicines Inc. (RVMD), 2.8%; Biogen Inc. (BIIB), 2.3% — together about 49% of the fund, per its Jun 30, 2026 SEC filing with weights rolled forward to today.
- How many holdings does IBB have?
- iShares Biotechnology ETF (IBB) held 247 positions as of its latest SEC N-PORT filing (Jun 30, 2026).
- How current are IBB's holdings?
- Funds disclose their full portfolio to the SEC on Form N-PORT; the quarter-end report becomes public about 60 days later. ChartRow anchors on the latest public filing (Jun 30, 2026) and rolls each weight forward daily by that holding's price move, so the weights shown estimate today rather than the filing date.
- Is ChartRow affiliated with IBB or BlackRock?
- No. ChartRow is independent and is not affiliated with, sponsored by, or endorsed by BlackRock or iShares Biotechnology ETF. Everything on this page is derived independently from the fund's public SEC filings; fund names and trademarks belong to their owners. For information only — not investment advice.